Abstract
Background
Sodium zirconium cyclosilicate (SZC), an ion-exchange resin, is effective in the control of hyperkalemia in adults with chronic kidney disease (CKD); reports of use in children are limited. Prolonged therapy with SZC to relax dietary potassium restriction in CKD has not been examined.
Methods
We conducted a retrospective chart review of patients 6 months to 18 years of age with CKD stage 4–5 or on dialysis (5D) administered SZC for sustained hyperkalemia (potassium ≥ 5.5 mEq/L, three consecutive values). Patients received SZC (0.5–10 g per dose; age-based) either short-term (< 30 days) or long-term (> 30 days).
Results
Twenty patients with median age 10.8 (inter-quartile range 3.9, 13.4) years were treated with SZC. Short-term SZC, for 5 (3, 19) days, was associated with safe management of dialysis catheter insertions (n = 5) and access dysfunction (n = 4), and was useful during palliative care (n = 1). Serum potassium levels decreased from 6.7 (6.1, 6.9) to 4.4 (3.7, 5.2) mEq/L (P < 0.001). Long-term SZC for 5.3 (4.2, 10.1) months achieved decline in serum potassium from 6.1 (5.8, 6.4) to 4.8 (4.2, 5.4) mEq/L (P < 0.001). SZC use was associated with liberalization of diet (n = 6) and was useful in patients with poor adherence to dietary restriction (n = 3). Adverse events or edema were not observed; serum sodium and blood pressure remained stable.
Conclusions
SZC was safe and effective for the management of acute and chronic hyperkalemia in children with CKD4-5/5D. Its use was associated with relaxation of dietary potassium restriction. Studies to examine its routine use to improve diet and nutritional status in children with CKD are required.
Graphical Abstract
Similar content being viewed by others
Data Availability
The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.
References
Kovesdy CP, Matsushita K, Sang Y, Brunskill NJ, Carrero JJ, Chodick G, Hasegawa T, Heerspink HL, Hirayama A, Landman GWD, Levin A, Nitsch D, Wheeler DC, Coresh J, Hallan SI, Shalev V, Grams ME, CKD Prognosis Consortium (2018) Serum potassium and adverse outcomes across the range of kidney function: a CKD Prognosis Consortium meta-analysis. Eur Heart J 39:1535–1542
Kurzinski KL, Xu Y, Ng DK, Furth SL, Schwartz GJ, Warady BA, CKiD Study Investigators (2023) Hyperkalemia in pediatric chronic kidney disease. Pediatr Nephrol 38:3083–3090
Belmar Vega L, Galabia ER, Bada da Silva J, Bentanachs Gonzalez M, Fernandez Fresnedo G, Pinera Haces C, Palomar Fontanet R, Ruiz San Millan JC, de Francisco ALM (2019) Epidemiology of hyperkalemia in chronic kidney disease. Nefrologia (Engl Ed) 39:277–286
Desloovere A, Renken-Terhaerdt J, Tuokkola J, Shaw V, Greenbaum LA, Haffner D, Anderson C, Nelms CL, Oosterveld MJS, Paglialonga F, Polderman N, Qizalbash L, Warady BA, Shroff R, Vande Walle J (2021) The dietary management of potassium in children with CKD stages 2–5 and on dialysis-clinical practice recommendations from the Pediatric Renal Nutrition Taskforce. Pediatr Nephrol 36:1331–1346
Laureati P, Xu Y, Trevisan M, Schalin L, Mariani I, Bellocco R, Sood MM, Barany P, Sjolander A, Evans M, Carrero JJ (2020) Initiation of sodium polystyrene sulphonate and the risk of gastrointestinal adverse events in advanced chronic kidney disease: a nationwide study. Nephrol Dial Transplant 35:1518–1526
Borrelli S, Matarazzo I, Lembo E, Peccarino L, Annoiato C, Scognamiglio MR, Foderini A, Ruotolo C, Franculli A, Capozzi F, Yavorskiy P, Merheb F, Provenzano M, La Manna G, De Nicola L, Minutolo R, Garofalo C (2022) Chronic hyperkaliemia in chronic kidney disease: an old concern with new answers. Int J Mol Sci 23:6378
Levien TL, Baker DE (2019) Sodium Zirconium Cyclosilicate. Hosp Pharm 54:12–19
Dong L, Xu W, Deng Y, Tan J, Qin W (2022) Efficacy and safety of potassium binders in the treatment of patients with chronic kidney disease and hyperkalemia. Eur J Pharmacol 931:175174
Packham DK, Rasmussen HS, Lavin PT, El-Shahawy MA, Roger SD, Block G, Qunibi W, Pergola P, Singh B (2015) Sodium zirconium cyclosilicate in hyperkalemia. N Engl J Med 372:222–231
Kim K, Fagerstrom J, Chen G, Lagunova Z, Furuland H, McEwan P (2022) Cost effectiveness of sodium zirconium cyclosilicate for the treatment of hyperkalaemia in patients with CKD in Norway and Sweden. BMC Nephrol 23:281
Kosiborod M, Rasmussen HS, Lavin P, Qunibi WY, Spinowitz B, Packham D, Roger SD, Yang A, Lerma E, Singh B (2014) Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia: the HARMONIZE randomized clinical trial. JAMA 312:2223–2233
Fishbane S, Ford M, Fukagawa M, McCafferty K, Rastogi A, Spinowitz B, Staroselskiy K, Vishnevskiy K, Lisovskaja V, Al-Shurbaji A, Guzman N, Bhandari S (2019) A phase 3b, randomized, double-blind, placebo-controlled study of sodium zirconium cyclosilicate for reducing the incidence of predialysis hyperkalemia. J Am Soc Nephrol 30:1723–1733
Liu B, Wang T, Chen Z (2022) Sodium zirconium cyclosilicate pretreatment for formula in vitro reduces potassium intake in infants with chronic kidney disease. Chin Med J (Engl) 135:3007–3009
Ash SR, Singh B, Lavin PT, Stavros F, Rasmussen HS (2015) A phase 2 study on the treatment of hyperkalemia in patients with chronic kidney disease suggests that the selective potassium trap, ZS-9, is safe and efficient. Kidney Int 88:404–411
Flynn JT, Kaelber DC, Baker-Smith CM, Blowey D, Carroll AE, Daniels SR, de Ferranti SD, Dionne JM, Falkner B, Flinn SK, Gidding SS, Goodwin C, Leu MG, Powers ME, Rea C, Samuels J, Simasek M, Thaker VV, Urbina EM, Subcommittee on Screening and Management of High Blood Pressure in Children (2017) Clinical practice guideline for screening and management of high blood pressure in children and adolescents. Pediatrics 140:e20171904
Freites-Martinez A, Santana N, Arias-Santiago S, Viera A (2021) Using the Common Terminology Criteria for Adverse Events (CTCAE - Version 5.0) to evaluate the severity of adverse events of anticancer therapies. Actas Dermosifiliogr (Engl Ed) 112:90–92
World Health Organization (2018) The use of the WHO-UMC system for standardised case causality assessment 2018. https://www.who.int/docs/default-source/medicines/pharmacovigilance/whocausality-assessment.pdf. Accessed 6 March 2023
Zannad F, Hsu BG, Maeda Y, Shin SK, Vishneva EM, Rensfeldt M, Eklund S, Zhao J (2020) Efficacy and safety of sodium zirconium cyclosilicate for hyperkalaemia: the randomized, placebo-controlled HARMONIZE-Global study. ESC Heart Fail 7:54–64
Yoo N, Song YB, Dubinsky I, Altshuler J (2023) Single dose of sodium zirconium cyclosilicate versus sodium polystyrene sulfonate in hospitalized patients with hyperkalemia. Ann Pharmacother 57:1044–1052
Spinowitz BS, Fishbane S, Pergola PE, Roger SD, Lerma EV, Butler J, von Haehling S, Adler SH, Zhao J, Singh B, Lavin PT, McCullough PA, Kosiborod M, Packham DK, ZS-005 Study Investigators (2019) Sodium zirconium cyclosilicate among individuals with hyperkalemia: a 12-month phase 3 study. Clin J Am Soc Nephrol 14:798–809
Roger SD, Lavin PT, Lerma EV, McCullough PA, Butler J, Spinowitz BS, von Haehling S, Kosiborod M, Zhao J, Fishbane S, Packham DK (2021) Long-term safety and efficacy of sodium zirconium cyclosilicate for hyperkalaemia in patients with mild/moderate versus severe/end-stage chronic kidney disease: comparative results from an open-label, Phase 3 study. Nephrol Dial Transplant 36:137–150
Kashihara N, Yamasaki Y, Osonoi T, Harada H, Shibagaki Y, Zhao J, Kim H, Yajima T, Sarai N (2021) A phase 3 multicenter open-label maintenance study to investigate the long-term safety of sodium zirconium cyclosilicate in Japanese subjects with hyperkalemia. Clin Exp Nephrol 25:140–149
Avesani CM, Heimbürger O, Sallstrom T, Danielsson A, Rubin C, Irving GF, Lindholm B, Stenvinkel P (2023) #2538 healthy plant-based diet in chronic kidney disease through use of sodium zirconium cyclosilicate (helpful trial): laboratorial findings. Nephrol Dial Transplant 38:i1176–i1177
Joshi S, Hashmi S, Shah S, Kalantar-Zadeh K (2020) Plant-based diets for prevention and management of chronic kidney disease. Curr Opin Nephrol Hypertens 29:16–21
Snauwaert E, Paglialonga F, Vande Walle J, Wan M, Desloovere A, Polderman N, Renken-Terhaerdt J, Shaw V, Shroff R (2023) The benefits of dietary fiber: the gastrointestinal tract and beyond. Pediatr Nephrol 38:2929–2938
Siirtola A, Virtanen SM, Ala-Houhala M, Koivisto AM, Solakivi T, Lehtimaki T, Holmberg C, Antikainen M, Salo MK (2008) Diet does not explain the high prevalence of dyslipidaemia in paediatric renal transplant recipients. Pediatr Nephrol 23:297–305
El Amouri A, Snauwaert E, Foulon A, Vande Moortel C, Van Dyck M, Van Hoeck K, Godefroid N, Glorieux G, Van Biesen W, Vande Walle J, Raes A, Eloot S (2021) Dietary fibre intake is associated with serum levels of uraemic toxins in children with chronic kidney disease. Toxins (Basel) 13:225
Clegg DJ, Headley SA, Germain MJ (2020) Impact of dietary potassium restrictions in CKD on clinical outcomes: benefits of a plant-based diet. Kidney Med 2:476–487
Morales E, Cravedi P, Manrique J (2021) Management of chronic hyperkalemia in patients with chronic kidney disease: an old problem with news options. Front Med (Lausanne) 8:653634
Nagard M, Singh B, Boulton DW (2021) Effects of sodium zirconium cyclosilicate on sodium and potassium excretion in healthy adults: a Phase 1 study. Clin Kidney J 14:1924–1931
Spinowitz B, McCafferty K, Fishbane S, Fukagawa M, Guzman N, Ford M, Rastogi A, Bhandari S (2022) Dose effect analysis of sodium zirconium cyclosilicate in hemodialysis patients. Hemodial Int 26:274–277
Roger SD, Spinowitz BS, Lerma EV, Fishbane S, Ash SR, Martins JG, Quinn CM, Packham DK (2021) Sodium zirconium cyclosilicate increases serum bicarbonate concentrations among patients with hyperkalaemia: exploratory analyses from three randomized, multi-dose, placebo-controlled trials. Nephrol Dial Transplant 36:871–883
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare no competing interests.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Khandelwal, P., Shah, S., McAlister, L. et al. Safety and efficacy of sodium zirconium cyclosilicate for the management of acute and chronic hyperkalemia in children with chronic kidney disease 4–5 and on dialysis. Pediatr Nephrol 39, 1213–1219 (2024). https://doi.org/10.1007/s00467-023-06176-6
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00467-023-06176-6